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ALTERATIONS OF DNA METHYLATION AND HISTONE
MODIFICATION IN CANCER
Epigenetics is an acquired modification of methylation and/or
acetylation of chromatin DNA or histone proteins, which reg-
ulates downstream gene expression. Epigenetic alterations can
be induced by aging, chronic inflammation and viral infection.
Aberrant DNA methylation and/or histone modification at the
CpG island promoter may induce inactivation of tumor suppres-
sor genes and play critical roles in the initiation and progression of
human cancer. In silico analysis is essential to investigate putative
genetic and epigenetic elements of tumor suppressor genes such
as Rb1 gene. This may contribute genetic and epigenetic informa-
tion modulating tissue-specific transcripts and expression levels
of genes (Hajjari et al., 2014). Genome-wide analysis of DNA
methylation by BeadChip assay is quite useful to identify aber-
rantly methylated genes in human cancers. HIST1H3J, POU4F2,
SHOX2, PHKG2, TLX3, and HOXA7 were identified as aber-
rantly methylated genes in human papillary thyroid cancers by
genome-wide analysis of DNAmethylation. In addition, papillary
thyroid cancers with preferential methylation were significantly
associated with mutations of the BRAF/RAS oncogenes. These
hypermethylated genes may constitute potential biomarkers for
papillary thyroid cancer (Kikuchi et al., 2013).
In 2010, the International Human Epigenome Consortium
(IHEC) was established to coordinate the production of refer-
ence maps of human epigenomes for key cellular states (http://
www.ihec-epigenomes.net/). In order to gain substantial cover-
age of the human epigenome, the IHEC is planning to decipher at
least 1000 epigenomes. Thesemultilayer-omics analyses including
genome, epigenome, transcriptome, proteome and metabolome
are important for elucidating the molecular carcinogenesis and
for exploring biomarkers and therapeutic targets for human
cancers (Kanai and Arai, 2014).
DYSREGULATION OF microRNAs (miRNAs) BY EPIGENETIC
ALTERATIONS IN CANCER
miRNAs are a class of endogenous non-coding RNAs that play
an important role in the regulation of several cellular, physiolog-
ical and developmental processes. Aberrant miRNA expression is
associated with many human diseases including cancer. Specific
miRNAs are aberrantly expressed and play roles as tumor sup-
pressors or oncogenes during carcinogenesis. Barrett’s esophagus
is considered to be a complication of gastroesophageal reflux
disease and a precursor lesion of esophageal adenocarcinoma.
Expression levels of miR-221 and miR-222 were increased when
cultured esophageal epithelial cells were exposed to bile acids,
which is one of the risk factors of esophageal adenocarcinoma.
These miRNAs are known to specifically target p27Kip1, which
inhibits the degradation of CDX2. Thus the degradation of CDX2
was enhanced by up-regulation ofmiR-221 andmiR-222 on expo-
sure of esophageal epithelial cells to bile acids (Matsuzaki and
Suzuki, 2014).
Important tumor suppressor miRNAs are silenced by epi-
genetic alterations, resulting in activation of target oncogenes
in human malignancies. But some oncogenic miRNAs such as
miR-196 family, miR-200 family and miR-519d are reported to
be up-regulated via DNA hypomethylation in various cancers.
Histone modifications also play important roles in the dysregu-
lation of miRNAs. Conversely, dysregulation of miRNAs such as
miR-152,miR-29 family andmiR-101 is related to epigenetic alter-
ations through targeting chromatin-modifying factors including
DNMT1, DNMT3A, DNMT3B, and EZH2 in cancer. Aberrant
methylation of miRNA genes could be a potential biomarker for
detecting cancer and predicting its outcome (Suzuki et al., 2013).
Several miRNAs are dysregulated in lung cancers in response to
DNA methylation and histone modification including methyla-
tion of histone H3 lysine 9 (H3K9) and H3K27. In lung cancer,
several miRNAs such as miR-9 and miR-34 family are silenced by
DNA methylation, whereas miR-212 is silenced by methylation of
H3K9 and H3K27 rather than DNA methylation (Watanabe and
Takai, 2013).
ALTERATIONS OF EPIGENETICS AND miRNAs IN CANCER
STEM CELL
Stem cells have an ability to perpetuate themselves through
self-renewal and to generate mature cells of various tissues
through differentiation. Accumulating evidence suggests that a
subpopulation of cancer cells with distinct stem-like properties
is responsible for tumor initiation, invasive growth, and metasta-
sis formation, which is defined as cancer stem cells (CSCs). CSCs
express specific cell surface markers including CD44, CD133, and
EpCAM. Recently, a novel 3D culture method for stem cells called
“organoid culture” has been developed. This culture method uses
a serum-free medium that includes only identified growth factors
such as R-spondin 1, EGF, and Noggin. R-spondin 1 is a ligand
for Lgr5, which is a marker for intestinal stem cells and an essen-
tial factor to activate Wnt signal in intestinal crypts. Intestinal
organoid culture enabled to expand normal or tumor epithelial
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cells in vitro with stem cell properties. This model will become
a powerful research tool in clarifying the molecular pathogenesis
and drug susceptibility of CSCs. Manipulation of cancer-related
genes in stem cells may reveal the molecular mechanism underly-
ing human carcinogenesis (Fujii and Sato, 2014). On the other
hand, the role of mesenchymal stem cells (MSCs) in cancer
development is still controversial. MSCs may promote tumor
progression through immune modulation, but other tumor sup-
pressive effects of MSCs have also been reported. Since systemi-
cally administered MSCs can be recruited and migrated toward
tumors, the incorporation of engineered MSCs can be used as
novel anti-tumor carriers for the development of tumor-targeted
therapies (Yagi and Kitagawa, 2013).
miRNAs including let-7 and miR-34a have been implicated
in the regulation of CSC properties by suppression of their tar-
get genes such as HMGA2, RAS, NOTCH1, and CD44. The
modulation of CSC gene expression by miRNAs could be a
novel therapeutic strategy targeting CSCs (Takahashi et al., 2014).
Glioblastomas show heterogeneous histological features, which
are considered to be associated with the presence of glioma
stem cells (GSCs). GSCs have an ability to self-renew and ini-
tiate the growth of gliomas and are resistant to conventional
chemotherapies. The oncogenic miRNAs including miR-17-92
cluster is involved in the regulation of GSC differentiation, apop-
tosis and proliferation by suppression of target genes such as
CTGF. The tumor suppressor miRNAs including miR-34a is also
dysregulated in GSCs. miR-34a directly inhibits the expression of
c-Met, Notch-1 and Notch-2 and involved in the differentiation
of GSCs. Long non-coding RNAs (lncRNAs) such as MEG3 and
CRNDE are also dysregulated in glioma tissues and may be asso-
ciated with the stemness of glioma cells (Katsushima and Kondo,
2014).
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